Faculty of Medicine Universitas Indonesia, Undergraduate Medical Program, Jakarta, Indonesia.
Faculty of Medicine Universitas Indonesia, Division of Endocrinology, Metabolism, and Diabetes, Department of Internal Medicine, Dr. Cipto Mangunkusumo National Referral Hospital, Jakarta, Indonesia.
Eur J Haematol. 2023 Jul;111(1):4-14. doi: 10.1111/ejh.13966. Epub 2023 Apr 10.
Hematopoietic stem cell (HSC) transplantation's success lies in its ability to induce immune reconstitution. To date, there is no review published to compare the immune reconstitution among the three sources of HSC: umbilical cord blood (UCB), bone marrow (BM), and peripheral blood (PB). The review aims to analyze the kinetic of immune reconstitution among UCB, PB, and BM in HSC transplant patients by focusing on natural killer (NK) cells, B and T lymphocytes, and neutrophils. A systematic review was conducted through five databases, searching for clinical trials and randomized control trials (RCTs) which analyze the kinetics of immune reconstitution in at least two sources. Selected studies were assessed with Cochrane RoB 2.0. This review included 14 studies, with a total of 2539 subjects. The PB group achieved the fastest time to neutrophil recovery, while the B-cell count was the highest in the UCB group. The T-cell count is the lowest in the BM group, and the NK-cell count does not differ significantly among the three HSC sources. Among the three sources of HSC, there is no superior HSC source for any immune reconstitution parameter. More studies must be conducted to compare the immune reconstitution and clinical outcomes of all HSC sources in specific diseases.
造血干细胞(HSC)移植的成功在于其诱导免疫重建的能力。迄今为止,尚无文献对三种来源的 HSC(脐带血(UCB)、骨髓(BM)和外周血(PB))的免疫重建进行比较。本综述旨在通过关注自然杀伤(NK)细胞、B 和 T 淋巴细胞以及中性粒细胞,分析 HSC 移植患者中 UCB、PB 和 BM 之间的免疫重建动力学。通过五个数据库进行系统综述,检索分析至少两种来源免疫重建动力学的临床试验和随机对照试验(RCT)。选择的研究采用 Cochrane RoB 2.0 进行评估。本综述共纳入 14 项研究,共 2539 例受试者。PB 组中性粒细胞恢复时间最快,而 UCB 组 B 细胞计数最高。BM 组 T 细胞计数最低,NK 细胞计数在三种 HSC 来源之间无显著差异。在三种 HSC 来源中,没有任何一种来源在任何免疫重建参数上都具有优势。必须进行更多的研究来比较所有 HSC 来源在特定疾病中的免疫重建和临床结局。